Beilu Pharma(SZ:300016)2024-09-09 08:39Group 1: Sales Performance - In the first half of 2024, the company's contrast agent products achieved sales revenue of 279.81 million yuan, a year-on-year increase of 10.85% [2] - The company's hypoglycemic products generated sales revenue of 66.73 million yuan, reflecting a significant growth of 58.44% [3] Group 2: Product Development and Market Expansion - The company has successfully expanded its gadolinium-based contrast agent product line, now including four MRI contrast agents, enhancing its market competitiveness [2] - The company plans to broaden the market for its Jiuwu Zhenxin Granules, targeting Southeast Asia, with ongoing registration efforts in Hong Kong and Thailand [3] Group 3: Financial Management and Future Outlook - The board of directors is continuously monitoring the convertible bond market dynamics and considering adjustments to the conversion price as per regulatory guidelines [3] - The company is committed to maintaining sufficient funds to ensure the repayment of convertible bonds' principal and interest in the future [3]